Nano-platforms delivering combination therapy to tumor cells

Thursday, 16 March 2017
Nano-platforms delivering combination therapy to tumor cells

Combinatorial therapy using multiple therapeutic agents simultaneously has emerged as a promising cornerstone in combating cancer as it can promote synergistic actions, improve target selectivity, overcome drug resistance without amplifying systemic toxicity and improve patient compliance. Recently, combinations of traditional chemotherapy with anti-angiogenic drugs that reduce new blood vessel formation in solid tumors have been adopted. Compared to physical mixtures of multiple free drugs, nanocarrier drug delivery systems carrying multiple drugs can offer many advantages. These include prolonged drug circulation half-life, better targeting, and accumulation at the tumor site, bypassing mechanisms of multidrug resistance, synchronized and controlled pharmacokinetics of each drug, resulting in improved combination efficacy,

The scope of the project englobes the preparation of a nanoscale drug delivery system, which would accommodate a combination of up to three drugs in the same platform at varying ratios. Physicochemical characterization of these carrier systems, including loading and kinetic release studies will be made. This is followed by biological characterization in vitro and using the tumor-bearing chorioallantoic membrane (CAM) model. In vivo studies may ultimately be performed with selected preparations and drug combinations.